IONS Overview
Upcoming Projects (IONS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IONS)
-
A Third Look: Delving into the results from OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema
Ticker: IONS
Executed On: Jun 28, 2024 at 06:00 PM EDT -
A Second Look: Delving into the results from OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema
Ticker: IONS
Executed On: Jun 13, 2024 at 10:30 AM EDT -
Delving into the results from OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema
Ticker: IONS
Executed On: Jun 12, 2024 at 12:30 PM EDT -
A Third View: Looking into the Phase 2 clinical trial of ION224, a DGAT2 antisense inhibitor being developed by Ionis Pharma for the treatment of MASH
Ticker: IONS
Executed On: Apr 26, 2024 at 08:30 AM EDT -
A Second View: Looking into the Phase 2 clinical trial of ION224, a DGAT2 antisense inhibitor being developed by Ionis Pharma for the treatment of MASH
Ticker: IONS
Executed On: Apr 08, 2024 at 12:00 PM EDT -
Looking into the Phase 2 clinical trial of ION224, a DGAT2 antisense inhibitor being developed by Ionis Pharma for the treatment of MASH
Ticker: IONS
Executed On: Apr 01, 2024 at 04:00 PM EDT -
Discussing the potential of AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy as an FDA approved option.
Tickers: AZN, IONS
Executed On: Mar 26, 2024 at 02:00 PM EDT -
A Third Look: Discussing the recently released data from the Phase 3 OASIS-HAE clinical trial of donidalorsen in patients with Hereditary Angioedema
Ticker: IONS
Executed On: Mar 01, 2024 at 08:00 AM EST -
A Second Look: Discussing the recently released data from the Phase 3 OASIS-HAE clinical trial of donidalorsen in patients with Hereditary Angioedema
Ticker: IONS
Executed On: Feb 29, 2024 at 03:15 PM EST -
Discussing the recently released data from the Phase 3 OASIS-HAE clinical trial of donidalorsen in patients with Hereditary Angioedema
Ticker: IONS
Executed On: Feb 15, 2024 at 02:00 PM EST -
A Third Look: Discussing the recently released data from the ongoing Phase 2 open-label extension clinical trial of donidalorsen in patients with Hereditary Angioedema
Ticker: IONS
Executed On: Dec 06, 2023 at 06:15 PM EST -
A Second Look: Discussing the recently released data from the ongoing Phase 2 open-label extension clinical trial of donidalorsen in patients with Hereditary Angioedema
Ticker: IONS
Executed On: Dec 06, 2023 at 12:00 PM EST -
Discussing the recently released data from the ongoing Phase 2 open-label extension clinical trial of donidalorsen in patients with Hereditary Angioedema
Ticker: IONS
Executed On: Dec 05, 2023 at 04:30 PM EST -
A second look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, IONS, PFE
Executed On: Oct 12, 2022 at 02:00 PM EDT -
A third discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 03:00 PM EDT -
A second discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 02:00 PM EDT -
Discussing the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 22, 2022 at 12:00 PM EDT -
A Fourth look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, NVS, IONS
Executed On: Aug 18, 2022 at 04:00 PM EDT -
A final look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 26, 2022 at 06:00 PM EDT -
A Third look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 22, 2022 at 01:15 PM EDT -
A Second look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 22, 2022 at 12:00 PM EDT -
A look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, TAK, IONS, CSLLY
Executed On: Jul 22, 2022 at 08:15 AM EDT -
Discussing the treatment landscape for Huntington's Disease with special attention to PTC 518 and AMT-130
Tickers: QURE, PTCT, IONS, RHHBY
Executed On: Jul 19, 2022 at 08:15 AM EDT
Upcoming & Overdue Catalysts (IONS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (IONS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
